The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
|Videos|July 13, 2018
Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC
Author(s)Leonard Gomella, MD
Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.
Advertisement
Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer (CRPC).
Advertisement
Related to this article
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The addition of olaparib to radium‐223 did not significantly impact PROs compared with radium‐223 alone in mCRPC with bone metastases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5